文献速递肝胆胰外科围术期管理与 ERAS

全胰腺切除术适应证与结局的演变:四十年单中心分析

Evolution of the Indications and Outcomes of Total Pancreatectomy.
PubMed 文献 · J Am Coll Surg · 2025-11-06

该研究分析梅奥诊所1988至2024年单阶段全胰腺切除术患者437例,分早期(1988-2009)与现代(2010-2024)两队列。现代队列年手术量增加,腺癌成为主要适应证,联合血管及多脏器切除比例显著升高,主要并发症增加,但腺癌5年总生存改善。

要点

  • 全胰腺切除术年手术量从早期平均8例增至现代平均21例。
  • 现代队列腺癌占60%,联合血管切除达53%,多脏器切除达24%。
  • 现代队列主要并发症27%,90天死亡率6.3%,腺癌生存改善。

核心结论

  • 全胰腺切除术使用近年大幅增加,主要因腺癌适应证扩大及新辅助治疗和解剖可切除标准扩展。
  • 手术复杂度显著增加并导致围术期并发症增多,联合血管切除时风险更高。
  • 需重视患者选择、术前教育和术后长期管理。

研究设计与样本

  • 回顾性队列研究,分析梅奥诊所罗切斯特院区1988至2024年接受单阶段全胰腺切除术的患者。
  • 共437例,早期队列(1988-2009)118例,现代队列(2010-2024)319例。

主要发现

  • 主要适应证:腺癌42%早期 vs 60%现代,导管内乳头状黏液性肿瘤31% vs 17%,慢性胰腺炎11% vs 13%(p < 0.001)。
  • 联合血管切除:9.3%早期(仅静脉) vs 53%现代(单纯静脉20%,动脉伴或不伴静脉33%;p < 0.001)。
  • 多脏器切除:<1%早期 vs 24%现代(p < 0.001)。
  • 主要并发症:13%早期 vs 27%现代(p = 0.018);90天死亡率:3.4%早期 vs 6.3%现代(p = 0.35)。
  • 腺癌患者从手术和诊断起算的5年中位总生存现代队列显著改善(p = 0.009和p < 0.001)。

关键数值与推荐

  • 末次HbA1c中位数:早期7.7 vs 现代7.3(p < 0.001)。
  • 生存超过1年的患者中,胰岛素泵使用:12%早期 vs 49%现代(p < 0.001)。

临床怎么用

  • 全胰腺切除术适应证扩大,尤其腺癌伴血管或多脏器切除时需严格选择患者。
  • 术前应充分教育患者手术风险及术后糖尿病管理,现代队列胰岛素泵使用增加。
  • 联合血管切除增加围术期并发症,术后需加强管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The first total pancreatectomy (TP) resulting in survival past the immediate postoperative period was performed at Mayo Clinic in 1944. Although still uncommonly performed, indications have recently fluctuated. We aimed to evaluate trends in TP use and outcomes over four decades. STUDY DESIGN: Patients who underwent single-stage TP at Mayo Clinic Rochester from 1988 to 2024 were analyzed in two cohorts: early era (EE, 1988 to 2009) and modern era (ME, 2010 to 2024). RESULTS: In total, 437 patients were identified: 118 during EE (mean 8 per year) and 319 during ME (mean 21 per year). Primary indications were adenocarcinoma (42% EE vs 60% ME), intraductal papillary mucinous neoplasm (31% EE vs 17% ME), and chronic pancreatitis (11% EE vs 13% ME; p < 0.001). Concurrent vascular resection was performed in 9.3% (EE; all venous only) vs 53% (ME; venous alone in 20% and arterial with or without venous in 33%; p < 0.001). Multivisceral resection was performed in <1% (EE) vs 24% (ME; p < 0.001). Major complications occurred in 13% (EE) vs 27% (ME; p = 0.018), and 90-day mortality was 3.4% (EE) vs 6.3% (ME; p = 0.35). For adenocarcinoma, 5-year median overall survival from both surgery and diagnosis was significantly improved in ME (p = 0.009 and p < 0.001, respectively). Median last HbA1c was 7.7 (EE) vs 7.3 (ME; p < 0.001). Among patients surviving more than 1 year, insulin pumps were used in 12% (EE) vs 49% (ME; p < 0.001). CONCLUSIONS: The use of TP has dramatically increased in recent years, primarily for adenocarcinoma alongside increased use of neoadjuvant therapy and ever-expanding criteria for anatomic resectability. Operative complexity has significantly increased with resultant increased perioperative morbidity. TP remains a higher-risk procedure, specifically with en bloc vascular resections, emphasizing the importance of appropriate patient selection, preoperative patient education, and thoughtful postoperative and long-term management.

来源:J Am Coll Surg,查看原文。版权归原作者所有。

引用

  1. Gudmundsdottir H, Adjei Antwi SK, Thiels CA, et al. Evolution of the Indications and Outcomes of Total Pancreatectomy. J Am Coll Surg. 2025. PMID: 41195873. doi:10.1097/XCS.0000000000001642

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。